Previous 10 | Next 10 |
2023-11-15 13:09:37 ET More on Atara Biotherapeutics Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity Atara's Balancing Act: Innovation On A Fiscal Tightrope Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript ...
2023-11-15 12:52:53 ET Penny stocks are often priced under $5 per share. They attract traders seeking big gains. But, these stocks also carry significant risks. One smart strategy is to track insider trading via SEC filings. Insiders, like directors and officers, often access vital, non...
2023-11-13 02:13:54 ET Summary Atara Biotherapeutics stock price dropped by 80% following failure of ATA188 in a phase 2 study in multiple sclerosis. This was an excessive reaction by the market in my opinion. ATRA's restructuring, tab-cel deal with Pierre Fabre, and lower future ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2023-11-09 12:48:14 ET Gainers: Intelligent Bio Solutions ( INBS ) +149% . Pineapple Financial ( PAPL ) +87% . Ramaco Resources ( METC ) +34% . Tempest Therapeutics ( TPST ) +30% . Fitell Corp ( FTEL ) +32% . Honest Company (...
2023-11-09 10:00:37 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
2023-11-08 20:37:35 ET More on Atara Biotherapeutics Atara's Balancing Act: Innovation On A Fiscal Tightrope Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript Atara Biotherapeutics: A Speculative Buy On Upcoming Phase 2 Multiple Sclerosis Readout ...
P rimary Endpoint of Confirmed Disability Improvement at 12 Months Not Achieved Company to Further Analyze Data and Evaluate Strategic Options for ATA188 Program with Focusing of Resources and Planned Expense Reductions Expected to Extend Cash Runway Beyond Q3 2025 Allogeneic ...
2023-11-06 03:10:05 ET Summary Atara Biotherapeutics sees European approval for tab-cel, signaling potential in oncology and autoimmune diseases, despite US regulatory hurdles. Recent financials show decreased losses, reduced expenses, but raise concern over possible future share ...
2023-11-04 11:45:28 ET Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Results Conference Call November 01, 2023 09:00 AM ET Company Participants Alex Chapman - VP, Corporate Communications & IR Dr. Pascal Touchon - President and CEO Eric Hyllengren - CFO Co...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...